StemCyte Overview

  • Founded
  • 1997
Founded
  • Status
  • Private
  • Employees
  • 207
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 9

StemCyte General Information

Description

Developer of regenerative cell therapy technologies designed to focus on stem cell transplantation and regenerative medicine. The company's technology deals in advancement of cord blood and cord tissue banking and stem cell transplants and therapies, enabling physicians to cure life threatening diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
  • 13800 Live Oak Avenue
  • Baldwin Park, CA 91706
  • United States
+1 (888) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

StemCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 000.00 Completed Generating Revenue
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Debt - General 23-Nov-2010 000.00 Completed Generating Revenue
7. Debt - General 01-Jun-2009 000 000.00 Completed Generating Revenue
6. Convertible Debt 02-Oct-2007 00.000 000.00 Completed Generating Revenue
5. Later Stage VC (Series 3) 14-Jul-2006 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 20-May-2002 00.000 000.00 0000 Completed Startup
3. Later Stage VC (Series C) 14-Feb-2002 00.00 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 02-Oct-2000 $5.46M $5.46M 000.00 Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view StemCyte’s complete valuation and funding history, request access »

StemCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 000 000 00 00.00 0.000
Series B 1,821,000 $0.001000 7% $3 $3 1x $2.5 11.51%
Series A 1,850,000 $0.001000 7% $2.5 $2.5 1x $1 24.36%
To view StemCyte’s complete cap table history, request access »

StemCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of regenerative cell therapy technologies designed to focus on stem cell transplantation and regenerative medi
Biotechnology
Baldwin Park, CA
207 As of 2020
000.00
00000 00000 000.00

00000000

henderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
0000000000000
Chennai, India
0000 As of 0000
00.00
0000000000 0 00.00

0000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
00000 0000000000 00000000
Waltham, MA
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemCyte Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
LifeCell International Venture Capital-Backed Chennai, India 0000 00.00 0000000000 0 00.00
0000000 Corporate Backed or Acquired Waltham, MA 000000&0
0000 00000 0000000 Private Equity-Backed Los Angeles, CA 000 00000 000000000000
00000000 00000 Formerly PE-Backed Singapore, Singapore 000 000.00 000000000 000.00
0000-0000 00000000 Corporation Oldsmar, FL 00 00000 000000&0
To view StemCyte’s complete competitors history, request access »

StemCyte Executive Team (10)

Name Title Board Seat Contact Info
Jonas Wang Ph.D Co-Chief Executive Officer, President & Chairman
Satish TN Chief Operating Officer, India
Wise Young Ph.D Chief Science and Medical Advisor
Kenneth Giacin Vice Chairman,Chief Business Development & Strategic Officer
Shinn-Zong Lin Chief Medical Officer,StemCyte Taiwan
You’re viewing 5 of 10 executive team members. Get the full list »

StemCyte Board Members (9)

Name Representing Role Since
Chris Tsai StemCyte Board Member 000 0000
Eli Wang StemCyte Board Member 000 0000
George Lee Ph.D Amkey Ventures Board Member 000 0000
Jonas Wang Ph.D StemCyte Co-Chief Executive Officer, President & Chairman 000 0000
Kenneth Giacin StemCyte Vice Chairman,Chief Business Development & Strategic Officer 000 0000
You’re viewing 5 of 9 board members. Get the full list »

StemCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemCyte Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amkey Ventures Venture Capital Minority 000 0000 000000 0
Fairbridge Venture Partners Venture Capital Minority 000 0000 000000 0
Kenson Ventures Venture Capital Minority 000 0000 000000 0
Kuwait Life Sciences Company Venture Capital Minority 000 0000 000000 0
Montage Capital Mezzanine Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »